Donafenib: First Approval

被引：0
|
作者：
Susan J. Keam
Sean Duggan
机构：
[1] Springer Nature,
来源：
Drugs | 2021年 / 81卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Donafenib (Zepsun®, 泽普生®), a deuterium derivative of sorafenib, is an oral small molecule multikinase inhibitor of multiple receptor kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and Raf kinases. Donafenib is being developed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Zelgen) for the treatment of various cancers, including hepatocellular carcinoma, colorectal cancer and thyroid cancer. In June 2021, donafenib received its first approval in China for the treatment of patients with unresectable hepatocellular carcinoma who have not previously received systemic treatment. This article summarizes the milestones in the development of donafenib leading to this first approval for use in unresectable hepatocellular carcinoma.
引用
收藏
页码：1915 / 1920
页数：5
相关论文
共 24 条
  • [1] Seebacher NA(2019)Clinical development of targeted and immune based anti-cancer therapies J Exp Clin Cancer Res 38 156-350
  • [2] Stacy AE(2019)Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities Mol Divers 23 341-693
  • [3] Porter GM(2019)Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial Pharmazie 74 688-604
  • [4] Zhong L(2021)Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial J Clin Oncol 85 593-S118
  • [5] Hou C(2020)A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours Cancer Chemother Pharmacol 31 S117-615
  • [6] Zhang L(2020)Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial [abstract no. P-86] Ann Oncol 35 e15682-undefined
  • [7] Liu J(2017)A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma [abstract no. e15682] J Clin Oncol 31 607-undefined
  • [8] Li X(2021)Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial Thyroid undefined undefined-undefined
  • [9] Zhang H(undefined)undefined undefined undefined undefined-undefined
  • [10] Qin S(undefined)undefined undefined undefined undefined-undefined
123